Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer of 1 of the following stages:~  * Metastatic disease (stage IV)~ * Inoperable locally advanced disease~    * Disease progression after prior neoadjuvant chemotherapy required~* Disease progression on or after trastuzumab (Herceptin®) based-therapy~  * Received 1-3 prior trastuzumab-based regimens~* HER2/neu-positive tumor, defined as 3+ by fluorescent in situ hybridization~* Measurable disease, defined as at least 1 lesion that can be measured in at least one dimension~* No clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT scan or MRI~  * Brain and/or leptomeningeal metastases allowed if patient has stable lesions after standard treatment (surgery or radiotherapy), is asymptomatic on neurological exam, and is not receiving corticosteroid therapy to control symptoms~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Male or female~* Menopausal status not specified~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* Alkaline phosphatase \< 5 times ULN~* AST and ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)~* LVEF above lower limit of normal by echocardiogram or MRI~* No clinical signs or symptoms of heart failure~* No uncontrolled hypertension (i.e., blood pressure ≥ 180/100 mm Hg)~* No significant valvular disease (i.e., aortic or mitral regurgitation of 3 or 4+/4+ severity or stenosis of either valve)~* No history of uncontrolled cardiac arrhythmia~* No symptomatic or asymptomatic myocardial infarction~* No angina pectoris requiring medication~* No other documented significant cardiac event~* No poorly controlled diabetes mellitus (i.e., fasting blood sugar ≥ 200 mg/dL)~* No history of hypersensitivity reaction to trastuzumab~* No AIDS~* No nonmalignant condition requiring ≥ 20 mg of prednisone (or equivalent)~* No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer~* No ongoing liver disease, including viral or other hepatitis, alcohol abuse, or cirrhosis~* No other serious medical illness~* No medical or psychiatric condition that would preclude study participation~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* More than 3 weeks since prior investigational anticancer agents~* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), major surgery, or immunotherapy~* More than 4 weeks since prior radiotherapy except short-course palliative radiotherapy for bone pain~* More than 2 weeks since prior and no concurrent oral hormonal therapy~* More than 4 weeks since prior fulvestrant~* No prior doxorubicin hydrochloride or doxorubicin HCl liposome at a cumulative dose of \> 360 mg/m\^2~* No prior mitoxantrone hydrochloride at a cumulative dose of \> 120 mg/m\^2~* No prior epirubicin hydrochloride at a cumulative dose of \> 600 mg/m\^2~* No prior idarubicin at a cumulative dose of \> 90 mg/m\^2~* No concurrent radiation therapy, including for symptomatic bone metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).